참고문헌
- Banito A, Pinto AE, Espadinha C, et al (2007). Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Clin Endocrinol (Oxf), 67, 706-11. https://doi.org/10.1111/j.1365-2265.2007.02949.x
- Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
- Boos LA, Dettmer M, Schmitt A, et al (2013). Diagnostic and prognostic implications of the PAX8-PPARgamma translocation in thyroid carcinomas-a TMA-based study of 226 cases. Histopathol, 63, 234-41. https://doi.org/10.1111/his.12150
- Castro P, Rebocho AP, Soares RJ, et al (2006). PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab, 91, 213-20.
- Castro P, Roque L, Magalhaes J, et al (2005). A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. Int J Surg Pathol, 13, 235-8. https://doi.org/10.1177/106689690501300301
- Cheung L, Messina M, Gill A, et al (2003). Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab, 88, 354-7. https://doi.org/10.1210/jc.2002-021020
- Dwight T, Thoppe SR, Foukakis T, et al (2003). Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab, 88, 4440-5. https://doi.org/10.1210/jc.2002-021690
- Eberhardt NL, Grebe SK, McIver B, et al (2010). The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol, 321, 50-56. https://doi.org/10.1016/j.mce.2009.10.013
- Kroll TG, Sarraf P, Pecciarini L, et al (2000). PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science, 289, 1357-60. https://doi.org/10.1126/science.289.5483.1357
- Lacroix L, Lazar V, Michiels S, et al (2005). Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol, 167, 223-31. https://doi.org/10.1016/S0002-9440(10)62967-7
- Lacroix L, Mian C, Barrier T, et al (2004). PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur J Endocrinol, 151, 367-74. https://doi.org/10.1530/eje.0.1510367
- Marques AR, Espadinha C, Catarino AL, et al (2002). Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab, 87, 3947-52.
- Nikiforova MN, Biddinger PW, Caudill CM, et al (2002). PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol, 26, 1016-23. https://doi.org/10.1097/00000478-200208000-00006
- Pacini F, Schlumberger M, Dralle H, et al (2006). European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 154, 787-803. https://doi.org/10.1530/eje.1.02158
- Papadopoulou F, Efthimiou E (2009). Thyroid cancer after external or internal ionizing irradiation. Hell J Nucl Med, 12, 266-70.
- Peters JL, Sutton AJ, Jones DR, et al (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676-80. https://doi.org/10.1001/jama.295.6.676
- Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603-5. https://doi.org/10.1007/s10654-010-9491-z